Objective Assess Aβ deposition longitudinally and explore its relationship with cognition and
disease progression. Methods Clinical follow‐up was obtained 20 ± 3 months after [ 11 C]…

Objective Elucidating the role of aggregated β‐amyloid in relation to gray matter atrophy is
crucial to the understanding of the pathological mechanisms of Alzheimer disease and for the …

Background Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from
a preclinical phase into a fully expressed clinical syndrome. We aimed to use longitudinal …

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, a participant of the
worldwide Alzheimer's Disease Neuroimaging Initiative (ADNI), recruited 1112 participants …

Objective Biomarkers for Alzheimer disease (AD) can detect the disease pathology in
asymptomatic subjects and individuals with mild cognitive impairment (MCI), but their cognitive …

Amyloid-β deposition in Alzheimer’s disease is thought to start while individuals are still
cognitively unimpaired and it is hypothesized that after an early phase of fast accumulation, a …

Objective: To investigate whether global and regional β-amyloid (Aβ) burden as measured
with 11 C Pittsburgh compound B (PIB) PET is associated with hippocampal atrophy …

See Derry and Kent (doi: 10.1093/awx167 ) for a scientific commentary on this article. The
large variance in cognitive deterioration in subjects who test positive for amyloid-β by positron …

Magnetic resonance (MR) imaging is a widely used medical imaging protocol that can be
configured to provide different contrasts between the tissues in human body. By setting …

Background Brain amyloid β (Aβ) deposition and neurodegeneration have been documented
in about 50–60% of cognitively healthy elderly individuals (aged 60 years or older). The …